Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 8/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.30 |
| ▸ | CCR3 | P51677 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20446526 | 0.87 | KLKB1 (0.52) | KLKB1TRPV1USP30LMNANPSR1 | |
| SCHEMBL20446521 | 0.87 | KLKB1 (0.52) | KLKB1TRPV1USP30LMNANPSR1 | |
| SCHEMBL20446528 | 0.87 | KLKB1 (0.52) | KLKB1TRPV1USP30LMNANPSR1 | |
| SCHEMBL29582315 | 0.81 | KLKB1 (0.55) | KLKB1 | |
| SCHEMBL28721772 | 0.81 | KLKB1 (0.55) | KLKB1 | |
| SCHEMBL20446523 | 0.75 | KLKB1 (0.50) | KLKB1LMNA | |
| SCHEMBL20584700 | 0.73 | KLKB1 (0.52) | KLKB1USP30LMNANPSR1 | |
| SCHEMBL20584697 | 0.73 | KLKB1 (0.52) | KLKB1USP30LMNANPSR1 | |
| SCHEMBL20584698 | 0.73 | KLKB1 (0.52) | KLKB1USP30LMNANPSR1 | |
| SCHEMBL29580856 | 0.73 | KLKB1 (0.52) | KLKB1USP30LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019022-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |